|
(Health-NewsWire.Net, May 26, 2015 ) Dallas, TX -- The report “Psoriasis – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projec
Psoriasis is a common skin condition that changes the life cycle of skin cells. Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms include flaking, inflammation, and thick, white, silvery, or red patches of skin. Psoriasis treatments include steroid creams, occlusion, light therapy and oral medications, such as biologics.
Companies discussed in this Psoriasis – Pipeline Review, H1 2015 report include: 4SC AG, AbGenomics International, Inc., Acceleron Pharma, Inc., Actelion Ltd, Addex Therapeutics Ltd, Advinus Therapeutics Ltd., Ajinomoto Pharmaceuticals Co., Ltd., AlbireoPharma, Allozyne, Inc., Almirall, S.A., AlphaMab Co., Ltd, Amgen Inc., Anacor Pharmaceuticals, Inc., Apexigen, Inc., ApoPharma Inc., Arena Pharmaceuticals, Inc., Argos Therapeutics, Inc., Arrien Pharmaceuticals, LLC, AuraSense Therapeutics, LLC, Avesthagen Limited, Avexxin AS, Basilea Pharmaceutica AG, BIOCAD, Biocon Limited, Bionomics Limited, Biotest AG, Biotie Therapies Corp., Boehringer Ingelheim GmbH, Brickell Biotech, Inc., Can-Fite BioPharma Ltd., Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., ChemoCentryx, Inc., ChironWells GmbH, Circassia Pharmaceuticals plc, Coherus BioSciences, Inc., Compugen Ltd., Convoy Therapeutics, Inc., Covagen AG, Creabilis SA, Crescendo Biologics Limited, Delenex Therapeutics AG, Deltanoid Pharmaceuticals Inc., Dermira Inc., Effimune SAS, Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Farmacija d.o.o. Tuzla, Fibrocell Science, Inc., Foamix Pharmaceuticals Ltd., Forward Pharma A/S, Gem Pharmaceuticals, LLC, Gene Signal International SA, Genentech, Inc., Genor BioPharma Co., Ltd., GlaxoSmithKline plc, GliaCure Inc., GlycoMar Limited, Grupo Ferrer Internacional, S.A., Hydra Biosciences, Inc., Idera Pharmaceuticals, Inc., Immune Response BioPharma, Inc., Invion Limited, ISDIN, Johnson & Johnson, Kadmon Corporation, LLC, KaloBios Pharmaceuticals, Inc., Kineta, Inc., Kinex Pharmaceuticals, LLC, Kyowa Hakko Kirin Co., Ltd., Lee's Pharmaceutical Holdings Limited, LegoChem Biosciences, Inc, LEO Pharma A/S, Lipidor AB, Lupin Limited, Lycera Corp., Mabion SA, Maruho Co., Ltd., MediGene AG, Merck KGaA, Mitsubishi Tanabe Pharma Corporation, NovaLead Pharma Pvt. Ltd., Novartis AG, Oncobiologics, Inc., Ono Pharmaceutical Co., Ltd., OPKO Health, Inc., Panacea Biotec Limited, Pfizer Inc., Pharis Biotec GmbH, Pharmedartis GmbH, Phenex Pharmaceuticals AG, Pieris AG and many more.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=375208 . (This is a premium report priced at US$2000 for a single user License.)
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
• The report provides a snapshot of the global therapeutic landscape of Psoriasis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Psoriasis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on Infectious Diseases Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .
RnR Market Research
Ritesh Tiwari
+18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
